Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration) Pipeline Review, H2 2016 - Research and Markets

DUBLIN--()--Research and Markets has announced the addition of the "Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration) - Pipeline Review, H2 2016" report to their offering.

Pharmaceutical and Healthcare latest pipeline guide Multiple System Atrophy - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Multiple System Atrophy (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Multiple System Atrophy (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I, Preclinical and Discovery stages are 1, 3, 3 and 1 respectively.

Multiple System Atrophy (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Key Topics Covered:

  1. Introduction
  2. Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration) Overview
  3. Therapeutics Development
  4. Pipeline Products for Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration) - Overview
  5. Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration) - Therapeutics under Development by Companies
  6. Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration) - Pipeline Products Glance
  7. Clinical Stage Products
  8. Early Stage Products
  9. Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration) - Products under Development by Companies
  10. Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration) - Companies Involved in Therapeutics Development
  • AFFiRiS AG
  • AstraZeneca Plc
  • Corestem Inc
  • MitoDys Therapeutics Ltd
  • Modag GmbH
  • Neuropore Therapies Inc
  • Prana Biotechnology Ltd

For more information about this report visit http://www.researchandmarkets.com/research/m3jhtr/multiple_system

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related Topics: Central Nervous System Drugs

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related Topics: Central Nervous System Drugs